Boneca Corporation Report issue

For profit Phase 2
Founded: Helsinki Finland (1995)
Status: Left NME R&D (2009)

Organization Overview

First Clinical Trial
2001
NCT00115440
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

boronophenylalanine (1 trial)

cetuximab (erbitux) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2